Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.

James S. Strong,Elvira L Vos,Caitlin A. McIntyre,Joanne F. Chou,Mithat Gonen,Laura H. Tang,Kevin C. Soares,Vinod P. Balachandran,T. Peter Kingham,Michael I. D’Angelica,William R. Jarnagin,Jeffrey A. Drebin,John W. Kunstman,Peter J. Allen,Alice C. Wei

Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.

2021

James S. Strong
Elvira L Vos
Caitlin A. McIntyre
Joanne F. Chou
Mithat Gonen
Laura H. Tang
Kevin C. Soares
Vinod P. Balachandran
T. Peter Kingham
Michael I. D’Angelica
William R. Jarnagin
Jeffrey A. Drebin
John W. Kunstman
Peter J. Allen
Alice C. Wei

BackgroundNeutrophil-to-lymphocyte ratio (NLR) has been reported as prognostic in pancreatic ductal adenocarcinoma (PDAC). Data about NLR changes during neoadjuvant therapy (NAT) and its relationsh...

Keywords:

pathological response
Medicine
pancreatic ductal adenocarcinoma
Neoadjuvant therapy
Cancer research
Neutrophil to lymphocyte ratio
Pancreatic cancer
neoadjuvant treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations